The primary goals were to investigate the progression of aCL IgM plasma titers in MDD patients throughout a course of antidepressant pharmacotherapy in comparison to HC subjects, and to determine if changes in aCL IgM correlated to changes in depressive symptoms. This evidence concerns the gene CD40LG and major depressive disorder.